Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 6Adenocarcinoma 6Neoplasms 5Lung Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Urethral Neoplasms 3Rectal Neoplasms 3Neoplasm Metastasis 3Liver Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Solid Tumors 2Sarcoma 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Biliary Tract Neoplasms 2Thymoma 1Solid Tumor 1Sarcoma, Synovial 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1

Interventions

Ramucirumab 2Nivolumab 2etirinotecan pegol 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Malignant Solid Tumor × Ramucirumab × Clear all
NCT01515306 2022-03-08

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
48 enrolled 17 charts
Other solid neoplasm

Malignant Solid Tumor

NCT01567163 2014-10-16

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Eli Lilly and Company

Phase 2 Completed
22 enrolled 15 charts
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡